WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p>
\nABL Diagnostics (FR001400AHX6 \u2013 \u201cABLD\u201d) announces the signing of a multi-year contract with a European pharmaceutical company in the field of neurodegenerative diseases. The contract relates to services operated by CDL Pharma and distributed by ABL Diagnostics.<\/p>
\nThis partnership is part of an international clinical program involving 30 centers across 11 countries in North America, Europe, and Asia, reflecting the Group\u2019s ability to support global multicenter studies.<\/p>
\nThe agreement includes an initial payment exceeding \u20ac100,000 upon signature, as well as a total contractual value that could reach approximately \u20ac2.7 million through 2031. Revenue will be recognized progressively based on the performance of the services under the contract and remains dependent on the effective progress of the clinical program.<\/p>
\nWithin this framework, CDL Pharma will deliver specialized services covering the operational management of international clinical trials, logistics and transportation of biological samples, design and management of sampling kits, cryogenic storage, as well as biomarker analysis. ABL Diagnostics acts as the distributor of these services to the end customer.<\/p>
\nThis contract contributes to enhancing the visibility of future revenue over multiple financial years and illustrates the progressive development of its value-added services in international clinical research.<\/p>
\nMohamed Errafyqy<\/b>, Sales and Operations Manager at ABL Diagnostics, commented:<\/p>
\n\u201cThis contract illustrates our ability to support complex international clinical programs and to deliver integrated service offerings.\u201d<\/p>
\nThe neurodegenerative diseases market is supported by favorable structural trends, notably driven by aging populations and the emergence of new therapeutic approaches. According to industry reports published by Mordor Intelligence and Research and Markets, this market could reach approximately USD 88 billion by 2030\u20132031.<\/p>
\nThese estimates are based on growth assumptions that remain uncertain and do not constitute a prediction of actual market developments or of ABL Diagnostics\u2019 potential share in this market.<\/p>
\nIn this context, demand for services associated with clinical trials, particularly in biological sample logistics and biomarker analysis, is expected to develop as clinical programs become more complex, without any assurance as to its scale or timing.<\/p>
\nDisclaimer<\/b>: The financial amounts disclosed are estimates based on current contractual terms. Their actual realization will depend on the progress of the clinical program and on the execution conditions of the contract. Market data are derived from external sources and are provided for information purposes only.<\/p>
\nAbout ABL Diagnostics (ABLD)<\/b><\/p>
\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p>
\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p>
\nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p>
\nAn expanding portfolio of microbiology products:<\/b><\/p> \nIntegrated Solutions<\/b><\/p> \nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p> \nABL Diagnostics SA<\/b> \nTel : +33 (0)7 83 64 68 50\n WOIPPY, France–(BUSINESS WIRE)–Regulatory News:\n
\n
\nABL Diagnostics (FR001400AHX6 \u2013 \u201cABLD\u201d) announces the signing of a multi-year contract with a European pharmaceutical company in the field of neurodegenerative diseases. The contract relates to services…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20126","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20126"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20126\/revisions"}],"predecessor-version":[{"id":20127,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20126\/revisions\/20127"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}